Evidence map›Paper›PMID 38540192›Full record

ReviewBiomedicines2024

Women with Gaucher Disease.

Maria Del Mar Meijon-Ortigueira, Isabel Solares, Cecilia Muñoz-Delgado, Sinziana Stanescu, Marta Morado, Cristina Pascual-Izquierdo, Lucía Villalon Blanco, Amaya Belanger Quintana, Covadonga Pérez Menéndez-Conde, Montserrat Morales-Conejo and 1 more

Open access · goldAbstract readReview
In one paragraph

Review in Biomedicines, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.0field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
  3. Gaucher disease, state of the art and perspectives.Journal of internal medicine · 2025
    Review
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 9 institutions in 1 country.

Maria Del Mar Meijon-OrtigueiraDepartment of Hematology, Hospital Universitario Ramón y Cajal-IRYCIS, 28034 Madrid, Spain.ORCID 0000-0002-2644-342X
Isabel SolaresDepartment of Internal Medicine, Clínica Universidad de Navarra, 28027 Madrid, Spain.
Cecilia Muñoz-DelgadoDepartment of Internal Medicine, Hospital Quirónsalud Sur, 28922 Madrid, Spain.
Sinziana StanescuPediatric Metabolic Unit, Hospital Universitario Ramón y Cajal, European Reference Center (MetabERN), 28034 Madrid, Spain.ORCID 0000-0003-0340-4580
Marta MoradoDepartment of Hematology, Hospital Universitario La Paz, 28046 Madrid, Spain.ORCID 0000-0002-9794-5339
Cristina Pascual-IzquierdoDepartment of Hematology, Hospital Universitario Gregorio Marañon, 28007 Madrid, Spain.ORCID 0000-0001-5442-4886
Lucía Villalon BlancoDepartment of Hematology, Hospital Universitario Fundación Alcorcón, 28922 Madrid, Spain.
Amaya Belanger QuintanaPediatric Metabolic Unit, Hospital Universitario Ramón y Cajal, European Reference Center (MetabERN), 28034 Madrid, Spain.
Covadonga Pérez Menéndez-CondePharmacy Department, Ramón y Cajal Hospital, IRYCIS, 28034 Madrid, Spain.ORCID 0000-0002-7785-0818
Montserrat Morales-ConejoCentro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), 28029 Madrid, Spain.
Jesús Villarrubia-EspinosaDepartment of Hematology, Hospital Universitario Ramón y Cajal-IRYCIS, 28034 Madrid, Spain.
Instituto Ramón y Cajal de Investigación Sanitaria · ESCentre for Biomedical Network Research on Rare Diseases · ESClinica Universidad de Navarra · ESHospital General Universitario Gregorio Marañón · ESHospital Universitario 12 De Octubre · ESHospital Universitario Fundación Alcorcón · ESHospital Universitario La Paz · ESHospital Universitario Ramón y Cajal · ESInstituto Cajal · ES

Funding

Sanofi (Spain) 2011/0062
6 · The paper itself

Abstract

Gaucher disease is an inherited disorder in which there is a deficiency of the enzyme glucocerebrosidase, which leads to the accumulation of glucosylceramide. Although much scientific evidence is now available, there is still limited data on the impact on the different life stages of women with this disease. Among other alterations, a delay in menarche has been described, although it has not been related to fertility problems. Menorrhagia is relatively frequent, being related to the presence of thrombocytopenia, thrombocytopathies or coagulation disorders. On the other hand, pregnancy planning is an increasingly frequent concern. All patients should undergo genetic counseling, and it is important to monitor the appearance or worsening of organomegaly, bone and hematologic abnormalities to establish clinical and therapeutic recommendations. Management during the puerperium will depend on the evolution of gestation, and, during the lactation period, the potential appearance of bone complications should be assessed. An early onset of menopause, compared to the general population, has also been described, which may accelerate the development of osteopenia. Finally, although the usual screening protocols for neoplasms are currently being performed, it is recommended to watch for early signs of liver or renal neoplasms when examining the results of imaging tests performed during evaluations for this disease.

Indexed as

enzyme-replacement therapy (ERT)Gaucher diseaselysosomal-storage disordersubstrate-reduction therapy (SRT)women

Identifiers

PMID38540192
PMCPMC10968251
OpenAlexW4392473374

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.